Incannex healthcare june 2023 quarterly activities report and appendix 4c cash flow statement

Melbourne, australia, july 28, 2023 (globe newswire) -- clinical stage pharmaceutical development company, incannex healthcare limited (asx: ihl) (nasdaq: ixhl), (‘incannex' or the ‘company'), is pleased to provide its quarterly activities report and appendix 4c for the period ended 30 june 2023. incannex is undertaking a multitude of u.s. food and drug administration (‘fda') research and development (‘r&d') programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals.
IXHL Ratings Summary
IXHL Quant Ranking